NCT07421401尚未招募1 期
A Randomized, Open-label, Fasting, Oral Administration, Single Dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and Safety After Administration of "BR1015-A" and Co-administration of "BR1015-3" and "BR1015-2" in Healthy Adult Volunteers
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 58
- 主要终点
- Cmax of Indapamide
研究概览
简要总结
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects with a body mass index (BMI) of more than 18.0 kg/m² and less than 30.0 kg/m² at the screening visit.
- •Subjects who provide written informed consent voluntarily after receiving and understanding sufficient explanation regarding the purpose and procedures of the clinical trial, the characteristics of the investigational product, and the expected adverse events.
- •Subjects who agree to use a highly effective method of contraception, excluding hormonal contraceptives, from the time of signing the written informed consent form until 14 days after the last administration of the investigational product, and who agree not to donate sperm or ova during this period. This requirement applies to the subject and, as applicable, to their spouse or sexual partner in order to prevent pregnancy.
排除标准
- •Subjects who have taken drugs that induce or inhibit metabolizing enzymes, such as barbiturates, within 30 days prior to the first administration of the investigational product, or who have taken any prescription drugs, over-the-counter drugs (OTC), herbal medicines, or dietary supplements within 10 days prior to the first administration that may interfere with the conduct of the study (however, participation may be allowed considering the pharmacokinetics and pharmacodynamics, including potential interactions with the investigational product and the half-life of concomitant drugs).
- •Subjects with a medical history of gastrointestinal resection or gastrointestinal diseases that may affect the absorption of drugs (except for simple appendectomy or hernia surgery).
- •Subjects who have participated in other clinical trials (including bioequivalence studies) and received investigational products within 6 months prior to the first administration of this study. For this criterion, the 6-month period is counted from the last administration date of the investigational product in the previous study.
- •Subjects who are unable to discontinue consumption of foods that may affect the absorption, distribution, metabolism, or excretion of the investigational product (e.g., raw grapefruit, grapefruit juice, or foods containing grapefruit) from 48 hours prior to the first administration of the investigational product until the collection of the last pharmacokinetic blood sample.
- •Subjects who, for reasons other than those specified in the inclusion and exclusion criteria above, are judged by the principal investigator (or a sub-investigator delegated by the principal investigator) to be unsuitable for participation in the clinical trial.
- •Female subjects who are pregnant, suspected of being pregnant, or currently lactating.
研究组 & 干预措施
BR1015-A
Experimental
干预措施: BR1015-A (Drug)
BR1015-3+BR1015-2
Active Comparator
干预措施: BR1015-3 (Drug)
BR1015-3+BR1015-2
Active Comparator
干预措施: BR1015-2 (Drug)
结局指标
主要结局
Cmax of Indapamide
时间窗: From pre-dose (0 hour) through 72 hours post-dose in each period (Periods 1-2).
Maximum Concentration of Drug in Plasma of Indapamide
AUCt of Fimasartan
时间窗: From pre-dose (0 hour) through 48 hours post-dose in each period (Periods 1-4).
Area under the Plasma Concentration-Time Curve from Time Zero to Time t of Fimasartan
AUCt of Indapamide
时间窗: From pre-dose (0 hour) through 72 hours post-dose in each period (Periods 1-2).
Area under the Plasma Concentration-Time Curve from Time Zero to Time t of Indapamide
Cmax of Fimasartan
时间窗: From pre-dose (0 hour) through 48 hours post-dose in each period (Periods 1-4).
Maximum Concentration of Drug in Plasma of Fimasartan
次要结局
未报告次要终点
研究者
相似试验
尚未招募
1 期
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsNCT07421375Boryung Pharmaceutical Co., Ltd58
尚未招募
1 期
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed ConditionsNCT07421388Boryung Pharmaceutical Co., Ltd48
已完成
1 期
Bioequivalence Study Between YHP2406 and YHR2501 in Healthy SubjectsNCT07265167Yuhan Corporation63
招募中
1 期
A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationsNCT07361237Tongji University36
已完成
1 期
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult VolunteersNCT07279636AlphaMol Science Ltd. (Shanghai)55